avalglucosidase alfa

Phase 3

Sanofi (SNY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Glycogen Storage Disease Type II

View Full Landscape

Drug Information

Target Indication

Glycogen Storage Disease Type II

Clinical Trial

NCT04910776

Last updated: 12/11/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/24/2022

Nexviadyme

Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Fexofenadine, Comparator = MontelukastPhase 3

Asthma

Teriflunomide 14 MG Oral Tablet [Aubagio]Phase 3

Multiple Sclerosis

Dupilumab/DupixentPhase 3

Asthma

dronedaronePhase 3

Atrial Fibrillation

AvidinPhase 3

Embolism

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts